Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | PREP | P48147 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3664438 | 0.82 | MAPK1 (0.36) | MAPK1HRH3CHRM2CHRM1CHRM3 | |
| SCHEMBL3642481 | 0.80 | MAPT (0.34) | CHRM2CHRM3 | |
| Hydrochloric Acid SCHEMBL8733450 | 0.79 | MAPT (0.33) | CHRM2CHRM3 | |
| SCHEMBL6588171 | 0.78 | MAPK1 (0.33) | MAPK1HRH3 | |
| SCHEMBL3665014 | 0.76 | ALDH1A1 (0.43) | MAPK1 | |
| Hydrochloric Acid SCHEMBL8731964 | 0.75 | ALDH1A1 (0.42) | MAPK1 | |
| SCHEMBL931733 | 0.74 | — | — | |
| SCHEMBL325433 | 0.71 | — | — | |
| SCHEMBL15330716 | 0.71 | — | — | |
| SCHEMBL25684409 | 0.71 | MAPK1 (0.37) | MAPK1HRH3CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114126620-A | FGFR inhibitors and methods of use thereof | 传达治疗有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-103237800-B | Amide derivatives and use thereof | MITSUBISHI TANABE PHARMA CORP. (JP) | 2015-10-21 | — | — | CN | disclosed |
| US-20070191416-A1 | Tetrahydropyridoindole derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191416-A1 | Tetrahydropyridoindole derivatives | TPH2, TPH1, HTR2C | MAPK1 3651/4885HRH3 290/4885CHRM2 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.